دورية أكاديمية
A retrospective study of S-1 and oxaliplatin combination chemotherapy in patients with refractory pancreatic cancer.
| العنوان: | A retrospective study of S-1 and oxaliplatin combination chemotherapy in patients with refractory pancreatic cancer. |
|---|---|
| المؤلفون: | Takahara N; Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan., Isayama H, Nakai Y, Sasaki T, Hamada T, Uchino R, Mizuno S, Miyabayashi K, Kogure H, Yamamoto N, Sasahira N, Hirano K, Ijichi H, Tateishi K, Tada M, Koike K |
| المصدر: | Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2013 Nov; Vol. 72 (5), pp. 985-90. Date of Electronic Publication: 2013 Sep 01. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Berlin : Springer Verlag Original Publication: Berlin, New York, Springer International. |
| مواضيع طبية MeSH: | Salvage Therapy*/adverse effects, Adenocarcinoma/*drug therapy , Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Organoplatinum Compounds/*therapeutic use , Oxonic Acid/*therapeutic use , Pancreatic Neoplasms/*drug therapy , Tegafur/*therapeutic use, Adenocarcinoma/secondary ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Drug Combinations ; Female ; Follow-Up Studies ; Humans ; Incidence ; Liver Neoplasms/secondary ; Lymphatic Metastasis ; Male ; Middle Aged ; Neutropenia/chemically induced ; Neutropenia/epidemiology ; Organoplatinum Compounds/administration & dosage ; Organoplatinum Compounds/adverse effects ; Oxaliplatin ; Oxonic Acid/administration & dosage ; Oxonic Acid/adverse effects ; Retrospective Studies ; Survival Analysis ; Tegafur/administration & dosage ; Tegafur/adverse effects ; Tokyo/epidemiology |
| مستخلص: | Purpose: The aim of this study was to evaluate S-1 and oxaliplatin combination chemotherapy (SOX) in patients with refractory pancreatic cancer (PC). Methods: Consecutive patients with advanced PC refractory to gemcitabine who were treated with oral S-1 (80 mg/m²) on days 1-14 and intravenous oxaliplatin (100 mg/m²) on day 1 every 3 weeks were studied retrospectively. The primary end point was the objective response rate (ORR). The secondary end points were progression-free survival (PFS), overall survival (OS), the disease control rate (DCR), and safety. Results: Between March 2009 and October 2011, 30 patients were treated with SOX, with a median of two courses (range 1-8). The ORR and DCR were 10.0 and 50.0 %, respectively. Median PFS and OS were 3.4 months (95 % confidence interval [CI] 1.3-5.3) and 5.0 months (95 % CI 3.4-7.4), respectively. The median PFS and OS were 5.6 and 9.1 months in patients receiving S-1 and oxaliplatin as a second-line treatment. Major grade 3 or 4 adverse events included neutropenia (10.0 %), anemia (3.3 %), and diarrhea (6.7 %). Conclusions: SOX was well tolerated and moderately effective in patients with refractory PC. |
| المشرفين على المادة: | 0 (Antineoplastic Agents) 0 (Drug Combinations) 0 (Organoplatinum Compounds) 04ZR38536J (Oxaliplatin) 150863-82-4 (S 1 (combination)) 1548R74NSZ (Tegafur) 5VT6420TIG (Oxonic Acid) |
| تواريخ الأحداث: | Date Created: 20130903 Date Completed: 20131216 Latest Revision: 20220408 |
| رمز التحديث: | 20240829 |
| DOI: | 10.1007/s00280-013-2278-7 |
| PMID: | 23995699 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1432-0843 |
|---|---|
| DOI: | 10.1007/s00280-013-2278-7 |